Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gabather ABFRA:5J2 3-Year ROIIC % is 214.55 as of Dec. 2025, which is 4% below its 10-year median of 224.48. The stock has 2 warning signs investors should review. Among 947 Drug Manufacturers companies, Gabather AB ranks better than 94.93% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Gabather AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 214.55%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Gabather AB's 3-Year ROIIC % or its related term are showing as below:
FRA:5J2's 3-Year ROIIC % is ranked better than 94.93% of 947
companies
in the Drug Manufacturers industry
Industry Median: 3.7
vs FRA:5J2: 214.55
Gabather AB (FRA:5J2) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Gabather AB 3-Year ROIIC % Related Terms
Gabather AB 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Gabather AB's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5J2 vs ZTS, UTHR, VTRS: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Gabather AB's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gabather AB 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gabather AB's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Gabather AB's 3-Year ROIIC % falls into.
Gabather AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -0.415 (Dec. 2025) - -0.778 (Dec. 2022) )
/
( 0.465 (Dec. 2025) - 0.288 (Dec. 2022) )
=
0.363
/
0.177
=
205.08%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Gabather AB (FRA:5J2) has a 3-Year ROIIC % of 214.55 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Gabather AB and its competitors. This is near median its historical median of 224.48. According to the industry distribution chart, Gabather AB ranks #48 out of 947 companies in the Drug Manufacturers industry, placing it in the top 5.1%.
Is Gabather AB's 3-Year ROIIC % too high?
Gabather AB's current 3-Year ROIIC % of 214.55 is near median its 10-year median of 224.48. The Drug Manufacturers industry median 3-Year ROIIC % is 3.70. Gabather AB's value of 214.55 is 5698.6% above this industry median. Based on the distribution chart, Gabather AB ranks #48 out of 947 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Gabather AB's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gabather AB ranks #48 out of 947 companies for 3-Year ROIIC %. This places Gabather AB in the top 5% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.70. Gabather AB's value of 214.55 is 5698.6% above this benchmark. While the company's 10-year median is 224.48 vs. the industry median of 3.70, Gabather AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.70, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gabather AB's current 3-Year ROIIC % of 214.55 is 5698.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Gabather AB and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gabather AB's current 3-Year ROIIC % is 214.55, which is near median its own 10-year median of 224.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gabather AB stock overvalued right now?
Gabather AB (FRA:5J2) has a current 3-Year ROIIC % of 214.55. The current 3-Year ROIIC % is 214.55, which is near median its 10-year median of 224.48 and 5698.6% above the Drug Manufacturers industry median of 3.70. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Gabather AB (FRA:5J2), the current 3-Year ROIIC % is 214.55 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gabather AB is engaged in developing novel drugs to treat several diseases originating in the central nervous system. It has four main focus areas anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as cognition-enhancing treatments, including for Alzheimer's disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5J2 has been successfully added to your 
